Propionic Acidemia

Clinical characteristics.

The spectrum of propionic acidemia (PA) ranges from neonatal-onset to late-onset disease.

• Neonatal-onset PA, the most common form, is characterized by a healthy newborn with poor feeding and decreased arousal in the first few days of life, followed by progressive encephalopathy of unexplained origin. Without prompt diagnosis and management, this is followed by progressive encephalopathy manifesting as lethargy, seizures, or coma that can result in death. It is frequently accompanied by metabolic acidosis with anion gap, lactic acidosis, ketonuria, hypoglycemia, hyperammonemia, and cytopenias.
• Individuals with late-onset PA may remain asymptomatic and suffer a metabolic crisis under catabolic stress (e.g., illness, surgery, fasting) or may experience a more insidious onset with the development of multiorgan complications including vomiting, protein intolerance, failure to thrive, hypotonia, developmental delays or regression, movement disorders, or cardiomyopathy.
• Isolated cardiomyopathy can be observed on rare occasion in the absence of clinical metabolic decompensation or neurocognitive deficits.

Manifestations of neonatal and late-onset PA over time can include growth impairment, intellectual disability, seizures, basal ganglia lesions, pancreatitis, and cardiomyopathy. Other rarely reported complications include optic atrophy, hearing loss, premature ovarian insufficiency, and chronic renal failure.

Diagnosis/testing.

PA is caused by deficiency of propionyl-CoA carboxylase (PCC), the enzyme that catalyzes the conversion of propionyl-CoA to methylmalonyl-CoA. Newborns with PA tested by expanded newborn screening have elevated C3 (propionylcarnitine). Testing of urine organic acids in persons who are symptomatic or those detected by newborn screening reveals elevated 3-hydroxypropionate and the presence of methylcitrate, tiglylglycine, propionylglycine, and lactic acid. Testing of plasma amino acids reveals elevated glycine. Confirmation of the diagnosis relies on detection of biallelic pathogenic variants in PCCA or PCCB or of deficient PCC enzymatic activity. In individuals with equivocal molecular genetic test results, a combination of enzymatic and molecular diagnostics may be necessary.

Management.

Treatment of manifestations: The treatment of individuals with acutely decompensated PA is a medical emergency: treat precipitating factors such as infection, dehydration, vomiting; reverse catabolism by providing intravenous glucose and lipids; manage protein intake to reduce propiogenic precursors; remove toxic compounds using nitrogen scavenger medications, extracorporeal detoxification, and/or intravenous carnitine; transfer to a center with biochemical genetics expertise and the ability to support urgent hemodialysis, especially if hyperammonemia is present.

Prevention of primary manifestations: Individualized dietary management should be directed by an experienced physician and metabolic dietician to control the intake of propiogenic substrates and to guide increased caloric intake during illness to prevent catabolism. G-tube placement is an effective strategy to facilitate the administration of medications and nutrition during acute decompensations and to improve adherence in chronic management of PA.

Medications may include: L-carnitine supplementation to enhance excretion of propionic acid and oral metronidazole to reduce propionate production by gut bacteria. Orthotopic liver transplantation (OLT) may be indicated in those with frequent metabolic decompensations, uncontrollable hyperammonemia, and/or poor growth.

Prevention of secondary complications: Consistent evaluation of the protein intake, depending on age, gender, severity of disorder and presence of other factors such as intercurrent illness, surgery, level of physical activity, and growth spurts to avoid insufficient or excessive protein restriction. Excessive protein restriction can result in deficiency of essential amino acids and impaired growth, as well as catabolism-induced metabolic decompensation.

Surveillance: Monitor closely patients with a catabolic stressor (fasting, fever, illness, injury, and surgery) to prevent and/or detect and manage metabolic decompensations early. Regularly assess: (1) growth, nutritional status, feeding ability, psychomotor development; (2) vision and hearing (3) cardiac function for signs of cardiomyopathy; (4) metabolic status by monitoring urine organic acids and plasma amino acids; (5) complete blood count; (6) renal function.

Agents/circumstances to avoid: Prolonged fasting, catabolic stressors, and excessive protein intake. Lactated Ringer’s solution is not recommended in patients with organic acidemias. In patients with QT abnormalities, avoid medications that can prolong the QT interval. Neuroleptic antiemetics (e.g., promethazine) can mask symptoms of progressive encephalopathy and are best avoided.

Evaluation of relatives at risk: Testing of at-risk sibs of a patient is warranted to allow for early diagnosis and treatment.

Genetic counseling.

Propionic acidemia is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known.

Suggestive Findings

Propionic acidemia (PA) should be suspected in individuals with any of the following presentations.

Neonatal-onset propionic acidemia (PA) is the most common clinical form of PA. In the first few days of life, infants present with:

• Lethargy
• Poor feeding
• Vomiting
• Hypotonia

Without treatment, this can progress to encephalopathy and cardiorespiratory failure.

Symptoms may be evident in the infant before NBS results are available.

Late-onset PA can present with a variety of concerns [Delgado et al 2007] including:

• Developmental delay
• Intellectual disability
• Failure to thrive
• Chronic gastrointestinal complaints
• Protein intolerance
• Acute psychosis
• Hypotonia
• Movement disorders such as dystonia and choreoathetosis

Acute decompensation can be precipitated by metabolic stressors including infection, injury, or surgery.

Cardiomyopathy can occur as an apparently isolated clinical phenomenon in previously healthy individuals without documented episodes of metabolic decompensation or neurocognitive deficits [Lee et al 2009, Laemmle et al 2014].

Testing

Newborn screening (NBS). Detection of PA in the neonatal period is possible using acylcarnitine analysis by tandem mass spectrometry (MS/MS) on dried blood spots.

• Acylcarnitine analysis reveals elevated propionylcarnitine (C3).
• Secondary markers including methionine, C3/C2, and C3/C16 ratios can be helpful to increase diagnostic accuracy [Couce et al 2011].

Biochemical analysis. Deficiency of propionyl-CoA carboxylase results in accumulation of propionic acid and propionyl-CoA related metabolites in plasma and urine, causing a wide range of laboratory test abnormalities (Figure 1).

Figure 1.

Metabolic pathway. Propionyl-CoA carboxylase (PCC) catalyzes the conversion of propionyl-CoA to methylmalonyl-CoA, which enters the Krebs cycle via succinyl-CoA. Sources of propionate include: valine, isoleucine, threonine, methionine, odd-chain fatty (more...)

Biochemical findings in propionic acidemia include:

• Plasma acylcarnitine profile: elevated propionylcarnitine (C3)
• Urine organic acids:
  • Elevated 3-hydroxypropionate
  • Presence of:
    • Methylcitrate
    • Tiglylglycine
    • Propionylglycine
    • Lactic acid
• Plasma amino acids: elevated glycine

Common laboratory abnormalities during acute decompensation include:

• High-anion gap metabolic acidosis
• Lactic acidosis
• Elevated plasma and urinary ketones
• Low to normal blood glucose concentration
• Hyperammonemia
• Neutropenia, anemia, and thrombocytopenia

Establishing the Diagnosis

In a proband who has the clinical, laboratory, and biochemical findings reviewed above and in Figure 2, the diagnosis of PA is established using the following strategies.

Figure 2.

Immediate management and testing algorithm to be pursued simultaneously after the clinical or laboratory suspicion of PA

I. Identification of biallelic pathogenic variants in PCCA or PCCB on molecular genetic testing (see Table 1). Molecular testing approaches can include serial single-gene testing, use of a multigene panel, and more comprehensive genomic testing:

• Serial single-gene testing can be considered if (1) mutation of a particular gene accounts for a large proportion of the condition or (2) factors such as clinical findings, laboratory findings, and ancestry indicate that mutation of a particular gene is most likely.
  For PA, neither gene is more common and there are no characteristic findings to distinguish between PCCA- and PCCB-associated PA.
  In instances where this testing approach is the only one available, sequence analysis of either PCCA or PCCB is performed first, followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.
• A multigene panel that includes PCCA and PCCB and other genes of interest (see Differential Diagnosis) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
  For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
• More comprehensive genomic testing (when available) including exome sequencing and genome sequencing may be considered if serial single-gene testing (and/or use of a multigene panel that includes PCCA and PCCB) fails to confirm a diagnosis in an individual with features of propionic acidemia. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

II. An alternative approach involves the assay of propionyl-CoA carboxylase (PCC) enzyme activity in lymphocytes or cultured skin fibroblasts followed by molecular diagnosis [Baumgartner et al 2014]. In individuals with equivocal molecular genetic test results, a combination of enzymatic and molecular diagnostics may be necessary.

Clinical Description

Propionic acidemia presents with a wide spectrum of symptoms and age of onset. The onset of symptoms in PA varies depending on several factors including residual enzymatic activity, intake of propiogenic precursors, and the occurrence of catabolic stressors. See Table 3a (pdf) and Table 3b (pdf) for a summary of major clinical findings in propionic acidemia (PA) and the reported frequency of symptoms.

Perinatal course. Reported maternal prenatal course, gestational age, and birth length, weight, and head circumference are similar to what is reported for unaffected infants [Kölker et al 2015a]. Increased frequency of miscarriages of affected fetuses is possible [Ottolenghi et al 2010].

Neonatal onset PA. A typical presentation of PA in the neonatal period is characterized by a healthy newborn with poor feeding and decreased arousal in the first few days of life, followed by progressive encephalopathy of unexplained origin. Without prompt diagnosis and management, neonates can develop progressive encephalopathy manifesting as lethargy, seizures, or coma that can result in death (see Table 2). Most individuals eventually diagnosed with PA become symptomatic in the first weeks of life, with 50%-60% exhibiting clinical signs at the time of the newborn screen report [Surtees et al 1992, Dionisi-Vici et al 2006, Grünert et al 2012].

See Table 3a (pdf) for a summary of the prevalence of major clinical findings during metabolic crisis in propionic acidemia.

Following initial clinical and biochemical stabilization, individuals with neonatal-onset PA may develop a range of symptoms affecting different organ systems. See following and Table 3b (pdf).

Late-onset PA. Residual activity of propionyl-CoA carboxylase may delay the onset of symptoms beyond the neonatal period.

Individuals with late-onset PA may remain asymptomatic and suffer a metabolic crisis under catabolic stress (e.g., illness, surgery, fasting) or experience a more insidious onset with the development of multiorgan complications as summarized in Table 4. See also Table 3b.

Metabolic decompensations. Children with PA can develop episodic metabolic decompensations, especially in the first years of life. Acidosis, hyperammonemia, pancreatitis, metabolic stroke, cardiomyopathy, bone marrow suppression, seizures, and encephalopathy can accompany acutely deranged metabolism. These episodes can be life-threatening and are often precipitated by illnesses, infections, surgery, or any stress augmenting catabolism. Infectious complications (e.g., sepsis or bacterial meningitis) often accompany metabolic crises and are the major contributors to mortality [Rousson & Guibaud 1984, North et al 1995]. The long-term cognitive outcome of individuals with PA is negatively correlated to the number of metabolic decompensations [Grünert et al 2012].

Growth. Linear growth delay and deceleration of the head circumference may become evident with age and can be seen in both earlier- and late-onset groups [Kölker et al 2015b]. Failure to thrive may be exacerbated by malnutrition secondary to feeding difficulties, recurrent emesis, excessive protein restriction and potentially iatrogenic amino acid imbalances [Manoli et al 2016].

Neurologic manifestations include developmental delay, developmental regression, intellectual disability, seizures, hypotonia, spasticity, and movement disorders [Grünert et al 2012, Pena & Burton 2012, Nizon et al 2013]. Developmental delays and neurologic dysfunction can be seen even in individuals without documented episodes of hyperammonemia or ketoacidosis [North et al 1995, Nyhan et al 1999, Schreiber et al 2012]. The prevalence of intellectual disability can vary between approximately 35% and 76% depending on the reported cohort [de Baulny et al 2005, Dionisi-Vici et al 2006, Touati et al 2006, Grünert et al 2012, Pena & Burton 2012].

• Seizures were reported in 13%-53% and EEG abnormalities in 40%-63% of Individuals with PA. Reported forms of seizures included infantile spasms, tonic-clonic, tonic, myoclonic, atonic, absence, and focal [Haberlandt et al 2009, Schreiber et al 2012, Karimzadeh et al 2014, Kölker et al 2015b]. Seizures were one of the presenting features of the initial metabolic episode in 12%-26% of cases [Grünert et al 2012, Kölker et al 2015a].
• Basal ganglia changes. Individuals with PA are predisposed to basal ganglia lesions, especially during episodes of acute encephalopathy or metabolic instability [Broomfield et al 2010]. Basal ganglia changes seen in 7%-56% of individuals may be preceded by an acute “stroke-like” episode and manifest as altered mental status, dystonia, choreoathetosis, or hemiplegia [de Baulny et al 2005, Scholl-Bürgi et al 2009, Grünert et al 2012, Pena & Burton 2012, Nizon et al 2013, Karimzadeh et al 2014]. The frequency of movement disorders in PA appears to be independent of the age of symptom onset [Kölker et al 2015a].
• Psychiatric manifestations. The prevalence of other comorbidities such as attention deficit disorder, autism spectrum disorder, anxiety, and acute psychosis is incompletely characterized [de Baulny et al 2005, Pena & Burton 2012, Nizon et al 2013, Vernon et al 2014]. Acute psychosis can be a presenting feature of PA in older individuals, especially in those not evaluated by newborn screen, thus warranting a high index of suspicion for this uncommon cause of psychosis in the general population [Shuaib et al 2012, Nizon et al 2013, Dejean de la Bâtie et al 2014].
• Brain MRI findings include delayed myelination, white matter changes, basal ganglia abnormalities, cerebellar hemorrhage, and cerebral atrophy [Schreiber et al 2012]. Clinically unstable individuals appear to be at higher risk of developing brain abnormalities. In a study of 17 PA individuals with clinical seizures, all had abnormal MRI findings and a history of more than ten metabolic decompensations [Haberlandt et al 2009]. Magnetic resonance spectroscopy (MRS) can reveal decreased myoinositol, N-acetylaspartate and elevated Glx (glutamine, glutamate, and gamma-aminobutyric acid) peaks in basal ganglia [Bergman et al 1996].

Cardiomyopathy has been recognized as a common complication of PA. Both dilated and hypertrophic cardiomyopathy have been reported [Romano et al 2010]. In the period between 2000 and 2015, its reported prevalence varied between 7% and 24% in various PA cohorts [Dionisi-Vici et al 2006, Romano et al 2010, Grünert et al 2012].

• Early clinical manifestations of cardiomyopathy include tachypnea, hepatomegaly, hypotension, tachycardia, or bradycardia.
• The mean age of onset of cardiomyopathy was seven years in a study by Romano et al [2010].
• The age of PA diagnosis, frequency of metabolic decompensation, and residual enzymatic activity do not correlate with presence/absence of cardiomyopathy in individuals with PA [Romano et al 2010].
• Rarely, cardiomyopathy can occur as an apparently isolated clinical phenomenon in previously healthy individuals without documented episodes of metabolic decompensation or neurocognitive deficits [Lee et al 2009, Laemmle et al 2014].
• Cardiomyopathy can progress to cardiac failure and may be associated with sudden death [Dionisi-Vici et al 2006].

Cardiac rhythm abnormalities. A prolonged QT interval is often detected in individuals with PA [Kölker et al 2015b]. This can be associated with syncope, arrhythmia, and cardiac arrest [Baumgartner et al 2007, Jameson & Walter 2008, Pena & Burton 2012].

Gastrointestinal manifestations

• Pancreatitis (reported in 3%-18% of individuals) may be recurrent and may present with anorexia, recurrent nausea, and abdominal pain [Dionisi-Vici et al 2006, Grünert et al 2012, Pena & Burton 2012]. In some individuals recurrent pancreatitis can lead to insulin-dependent diabetes.
• Poor feeding and lack of appetite are common, affecting up to 76% of affected individuals [Touati et al 2006].
• Emesis and diarrhea are commonly reported in individuals with PA, becoming a recurrent problem in approximately 6% [Kölker et al 2015b].
• Liver issues include hepatomegaly, hypoalbuminemia, and abnormal liver function tests (ALT, AST, GGT, INR, and bilirubin) [Karimzadeh et al 2014, Kölker et al 2015b]. The etiology of hepatic dysfunction has not been determined with certainty but may include the inherent metabolic derangement as well as cardiac dysfunction in individuals with cardiomyopathy.

Renal abnormalities have been infrequently documented and are likely underreported. Examples have included impaired renal function [Lehnert et al 1994], chronic renal insufficiency leading to renal transplant at age 42 years [Lam et al 2011], and progressive kidney disease in the third decade of life [Vernon et al 2014].

Hematologic abnormalities. Although anemia, leukopenia, and thrombocytopenia are common, pancytopenia is seen less frequently, in 6%-15% of individuals [Grünert et al 2012, Pena & Burton 2012, Karimzadeh et al 2014, Kölker et al 2015b]. Myelodysplastic changes in the bone marrow are uncommon [Stork et al 1986, Sipahi et al 2004].

Immune system. Early retrospective data suggested high frequency of recurrent infections seen in 60%-80% of affected individuals [Lehnert et al 1994, Al Essa et al 1998]. Factors predisposing to infectious complications were likely diverse and included bone marrow suppression, immune dysfunction instigated by propionic acid metabolites, indwelling catheters (e.g., central lines), frequent hospitalizations, and potential nutritional deficiencies caused by dietary modification. Although staphylococcal scalded skin syndrome and Candida skin infections were reported in the earlier literature [Lehnert et al 1994, Al Essa et al 1998], more recent natural history studies suggest that such complications are uncommon [Baumgartner et al 2014, Kölker et al 2015b].

Hypogammaglobulinemia, B-cell lymphopenia, decreased CD4 and CD8 counts, and abnormal CD4/CD8 ratio have been described [Müller et al 1980, Griffin et al 1996, Al Essa et al 1998, Pena & Burton 2012]. Hypogammaglobulinemia, reported in as many as 15% of affected individuals, has required treatment with immunoglobulin in some cases [Müller et al 1980, Raby et al 1994, Pena & Burton 2012].

Ophthalmologic manifestations. Eye findings include dyschromatopsia, optic atrophy, scotomas, abnormal electroretinogram, visual evoked potentials, and optical coherent tomography. In addition, optic tract and cortical abnormalities have been occasionally noted [Noval et al 2013, Arias et al 2014].

Optic neuropathy occurs in 11%-25% [Pena & Burton 2012, Martinez Alvarez et al 2016]. The onset of optic neuropathy can be acute or insidious; further deterioration can occur during metabolic decompensations triggered by infections or surgery [Noval et al 2013, Martinez Alvarez et al 2016]. The mean age of diagnosis is approximately 13 years (range 2-24 years) [Arias et al 2014, Martinez Alvarez et al 2016].

Hearing loss. Sensorineural hearing loss was reported in 1% and 13% in two large cohorts of individuals with PA [Grünert et al 2012, Kölker et al 2015b].

Musculoskeletal system. Severe osteopenia and osteoporosis have been described in adults with PA [Grünert et al 2012].

Dermatologic manifestations resembling acrodermatitis enteropathica are frequently associated with deficiency of essential amino acids, particularly isoleucine, which can be inadvertently over-restricted in the diet of persons with PA [Domínguez-Cruz et al 2011].

Other rare complications. Isolated case reports describe clinical findings that could be causally associated with propionic acidemia, but require further characterization: muscle lipidosis [de Baulny et al 2005]; myopathy [Martinez Alvarez et al 2016]; premature ovarian insufficiency [Lam et al 2011]; oligomenorrhea [Martín-Hernández et al 2009]; hypothyroidism [Vernon et al 2014, Martinez Alvarez et al 2016]; parathyroid hormone resistance resolving after hemodialysis [Griffin et al 1996].

Life span. PA confers a high risk of mortality. Reported mortality rates appear to be on the decline: 41%-90% in the 1980-90s, 17%-72% in 2000s, and 7%-12% in early 2010s [Rousson & Guibaud 1984, Surtees et al 1992, van der Meer et al 1996, Pérez-Cerdá et al 2000, Sass et al 2004, de Baulny et al 2005, Dionisi-Vici et al 2006, Touati et al 2006, Grünert et al 2012]. Observed decline in reported mortality likely reflects the length of follow up, introduction of newborn screening, expansion of the PA phenotype, proactive medical management, and elective liver transplantation.

Long-term adult outcomes. Systematic studies of adult individuals with PA are lacking. Early reports suggest that adults with PA can experience significant osteopenia, osteoporosis, renal failure, and premature ovarian failure [Martín-Hernández et al 2009, Lam et al 2011, Vernon et al 2014].

Atypical presentation. Apparently asymptomatic individuals with PA (9%-17% in different cohorts) represent a heterogeneous group consisting of otherwise healthy infants identified after newborn screening, sibs ascertained through evaluation prompted by diagnosis of the proband, and individuals with a diagnosis of PA with incomplete clinical characterization [Grünert et al 2012, Kölker et al 2015a].

Genotype-Phenotype Correlations

Although precise genotype-phenotype correlations do not exist, some general comments related to molecular genetics are relevant.

• Null variants (PCCA: p.Arg313Ter, p.Ser562Ter; PCCB: p.Gly406fs, p.Gly94Ter, and out-of-frame small deletions/insertions, genomic abnormalities) result in loss-of-function alleles and are associated with a more severe form of PA [Desviat et al 2004, Desviat et al 2009].
• Homozygous missense pathogenic variants, in which partial enzymatic activity is retained (PCCA: p.Ala138Thr, p.Ile164Thr, p.Arg288Gly; PCCB: p.Asn536Asp) have been associated with a less severe phenotype.
• Some missense pathogenic variants (PCCB p.Gly112Asp, p.Arg512Cys, and p.Leu519Pro) which affect heterododecamer formation can result in undetectable PCC enzyme activity and severe phenotype [Muro et al 2001].

A homozygous PCCB variant in Amish and Mennonite populations, p.Asn536Asp, is associated with high residual PCC activity. It confers a lower risk of developing metabolic crisis, but can lead to late-onset cardiomyopathy.

A homozygous PCCB variant, p.Tyr435Cys, has been detected in apparently asymptomatic or mildly affected children identified through newborn screening in Japan [Yorifuji et al 2002].

Nomenclature

Propionic acidemia and propionyl-CoA carboxylase deficiency are the two most common terms used to describe the condition. Ketotic hyperglycinemia was used in the 1960s before defects in propionyl-CoA carboxylase were determined to be the underlying cause of PA [Hsia et al 1969]. The term propionic aciduria is used infrequently.

Prevalence

Worldwide, the incidence of PA varies widely. The estimated live-birth incidence of PA is 1:105,000-1:130,000 in the US [Chace et al 2001, Couce et al 2011], 1:166,000 in Italy [Dionisi-Vici et al 2002] and 1:250,000 in Germany [Schulze et al 2003].

The incidence appears to be higher in the Middle East. In the United Arab Emirates, the birth incidence of PA is ~1:20,000-1:45,000 [Al-Shamsi et al 2014]. In Saudi Arabia the birth incidence is 1:28,000 [Rashed 2001], and can be higher in some Saudi tribes: 1:2000-1:5000 [Zayed 2015].

In Japan, the live birth incidence of severe propionic acidemia is 1:465,000, but increases to 1:17,400 when combined with an apparently asymptomatic form of PA identified through newborn screening [Yorifuji et al 2002].

The highest reported birth incidence is found among the Greenlandic Inuits: 1:1000 [Ravn et al 2000].

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs of an individual diagnosed with PA the following evaluations are recommended (see Figure 2) if they have not already been completed:

• Blood gas with base balance, electrolytes with anion gap, glucose, plasma ammonia, calcium, phosphorus, urine ketones
• Plasma amino acids, total and free carnitine and acylcarnitine profile, and urine organic acid analysis
• Complete blood count to evaluate for cytopenias
• Consider initiating an evaluation for sepsis if the CBC and individual’s clinical signs suggest that infection is likely
• Amylase and lipase to evaluate for pancreatitis
• Consultation with a clinical geneticist and/or genetic counselor

Once the patient becomes stable, evaluations include the following:

• Clinical assessment of growth parameters, ability to feed, the need for G-tube placement, and neurologic status.
• Laboratory assessment of nutritional status (calcium, phosphorus, albumin, prealbumin, plasma amino acids, vitamin levels [including thiamine and 25-hydroxyvitamin D], iron panel, and minerals and renal function); complete blood count to monitor for cytopenias
• Clinical evaluation for cardiomyopathy and arrhythmia with ECG, 24-hour Holter monitor, echocardiogram
• EEG and brain MRI in symptomatic individuals
• Developmental evaluation
• Dilated eye examination
• Hearing evaluation
• Immunology consult

Other

• Complete adherence to regional immunization schedules and influenza vaccination is indicated [Baumgartner et al 2014].
• Maintain a high index of suspicion for endocrine, immune, and renal problems and address accordingly.

Treatment of Manifestations

Neonatal/acute decompensation. Birth, infections, trauma, surgery, postpartum recovery, or other forms of stress and hormonal changes can result in a catabolic response that leads, among other things, to protein breakdown with release of propiogenic amino acids that cannot be metabolized in PA. The goal of acute management is to reverse this process through promotion of anabolism and removal of toxic intermediates. The treatment of individuals with acutely decompensated PA is a medical emergency and requires a transfer to a center with biochemical genetics expertise and the ability to support urgent hemodialysis, especially if hyperammonemia is present.

In-patient management

• Assess and manage ventilation and circulation as necessary.
• Treat precipitating factors (fever, infection, dehydration, pain, vomiting, and other sources of stress).
• Determine the need for sepsis workup and antibiotics.
• Reverse catabolism by giving intravenous glucose and lipids.
  • The volume, glucose content and electrolyte composition of intravenous fluids is determined by age, target glucose infusion rate, cardiovascular status, renal condition, and co-administration of other medications.
  • Intravenous D10 ½ normal saline typically between 100% and 150% of the maintenance requirements is a common starting fluid. Dextrose solutions exceeding the concentration of 12.5% require a central line placement. The target glucose infusion rates varies by age [Baumgartner et al 2014].
  • Additional calories can be provided using parenteral lipid emulsion.
  • The use of intravenous insulin drip may be needed to maintain euglycemia and promote anabolism.
• Manage protein intake to reduce propiogenic precursors; avoidance of protein transiently for <24-36 hours may be required.
  • Transition to enteral feedings should be commenced as soon as they are tolerated (see Prevention of Primary Manifestations, Dietary management).
  • If transition to enteral feedings within 48 hours is not possible, total parenteral nutrition is required.
  • Parenteral amino acid solutions are prescribed based on the recommended daily intake of age-appropriate energy, protein, isoleucine, valine, methionine, and threonine and adjusted using the daily and weekly growth data and plasma amino acid concentrations.
• Remove toxic compounds.
  • Pharmacologic detoxification:
    • Nitrogen scavenger medications (sodium benzoate, sodium phenylacetate, sodium phenylbutyrate